JPMorgan Chase & Co. started coverage on shares of Omada Health (NASDAQ:OMDA - Free Report) in a report published on Tuesday morning, MarketBeat.com reports. The firm issued an overweight rating and a $19.00 price objective on the stock.
Other analysts have also recently issued research reports about the company. Canaccord Genuity Group assumed coverage on Omada Health in a research report on Tuesday. They issued a "buy" rating and a $27.00 price target for the company. Wall Street Zen raised shares of Omada Health to a "hold" rating in a report on Monday, June 16th. The Goldman Sachs Group initiated coverage on shares of Omada Health in a research note on Tuesday. They set a "buy" rating and a $29.00 target price on the stock. Needham & Company LLC began coverage on shares of Omada Health in a report on Tuesday. They set a "buy" rating and a $23.00 price target on the stock. Finally, Barclays assumed coverage on shares of Omada Health in a research note on Tuesday. They issued an "overweight" rating and a $21.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Omada Health presently has an average rating of "Moderate Buy" and a consensus target price of $23.57.
View Our Latest Stock Analysis on Omada Health
Omada Health Stock Performance
Shares of NASDAQ:OMDA traded up $0.18 during midday trading on Tuesday, hitting $18.43. The company had a trading volume of 180,446 shares, compared to its average volume of 1,149,361. Omada Health has a 12-month low of $14.14 and a 12-month high of $28.40.
About Omada Health
(
Get Free Report)
Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.
Featured Stories

Before you consider Omada Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omada Health wasn't on the list.
While Omada Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.